Form D · Pharmaceuticals

Satsuma Pharmaceuticals, Inc.

South San Francisco, CA · CIK 0001692830

Offering snapshot reported Feb 12, 2018 · SEC filing

Reported sold
$12.1M
Offering amount: $12.3M
Investors reported
4
Form D · investor count
Minimum accepted
$1
Reported outside-investor minimum
First sale
Dec 16, 2016
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$6.07M$12.1MDec 29, 2016: $6,000,000.00Dec 29, 2016Feb 12, 2018: $12,134,401.00Feb 12, 2018

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$6,000,000 → $12,134,401
  • Reported investors3 → 4

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 12, 2018Amendment$12,134,401$6,134,401vs Dec 29, 20164SEC filing
Dec 29, 2016Initial$6,000,000No comparison3SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-277219

Source: Form D, filed Feb 12, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Tadayoshi Iwashima Executive
Thomas King Director
John Kollins Director, Executive
Heath Lukatch Director
Michael Riebe Director
Rajeev Shah Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
400 Oyster Point Blvd. Suite 221
South San Francisco, CA, 94080